Kymberli Brock, NP
Family · Wasilla, AKNPI 1619972478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$590
- GSK$402
- Astellas Pharma US Inc$399
- Merck$265
- Amgen$239
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,17498%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$5,254 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $56,020 |
| OzempicSemaglutide | 25 | $45,720 |
| XareltoRivaroxaban | 27 | $35,611 |
| ZenpepLipase/Protease/Amylase | 13 | $31,644 |
| MyrbetriqMirabegron | 61 | $26,102 |
| JanuviaSitagliptin Phosphate | 18 | $24,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,606 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $21,180 |
| MounjaroTirzepatide | 18 | $20,514 |
| JardianceEmpagliflozin | 20 | $20,386 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,711 |
| Celecoxib | 71 | $3,956 |
| TirosintLevothyroxine Sodium | 11 | $3,785 |
| SynthroidLevothyroxine Sodium | 28 | $2,801 |
| Estradiol | 28 | $2,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $56,02048 claims |
| Novo NordiskOzempic | $181 | $45,72025 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $402 | $38,31658 claims |
| Johnson & JohnsonXarelto | $124 | $35,61127 claims |
| Aimmune Therapeutics, Inc.Zenpep | $110 | $31,64413 claims |
| Astellas Pharma US IncMyrbetriq | $399 | $26,10261 claims |
| MerckJanuvia | $265 | $24,80818 claims |
| AstraZenecaBreztri Aerosphere | $1,064 | $21,18030 claims |
| Lilly USA, LLCMounjaro | $55 | $20,51418 claims |
| Boehringer IngelheimJardiance | $13 | $20,38620 claims |
| AbbVieSynthroid, Armour Thyroid | $590 | $4,11843 claims |
| IBSA Pharma Inc.Tirosint | $33 | $3,78511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 315 family providers in Alaska.
Other family in Wasilla
- Sarah NielsenWasilla$4K
- Alison ArmourWasilla$4K
- Stephanie McQuillinWasilla$4K
- Liudmila FedorWasilla$4K
- Debby MaloneyWasilla$3K
- Alysa SonnentagWasilla$3K
- Christine BailesWasilla$2K
- Lisa Bouyea-FranciesWasilla$2K
- Kathleen MatthewsWasilla$2K
- Erica MuchaWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.